Popular on EntSun
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1 - 212
- Guests Can Save 10 Percent Off New Vacation Rental Homes at KeysCaribbean's Village at Hawks Cay Villas - 192
- Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles - 188
- Metro Detroit teen Lola Winters turns viral TikTok fame into a sold-out clothing brand - 172
- MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread - 152
- America's Leading Annuity Expert Carlton Cap Averil II Joins Tom Hegna on "Financial Freedom with Tom Hegna" - 139
- Touch Massage London Unveils Premium Local Massage Services to Transform Wellbeing Across the Capital - 130
- ProfileSpider Launches Powerful One-Click Profile Scraper for Recruiters and Growth Teams - 130
- Make This Fall Your Most Stylish Yet with Nickel-Free Bestsellers from Nickel Smart - 124
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology - 116
Similar on EntSun
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Gold Standard Diagnostics Launches AIX1000 2.1® with Extra High Titer RPR Testing
EntSun News/11076490
Gold Standard Diagnostics receives FDA clearance for AIX1000® 2.1-- now with extra high titer capabilites.
DAVIS, Calif. - EntSun -- Gold Standard Diagnostics Launches AIX1000 2.1® with Extra High Titer RPR Testing and Enhanced Workflow Features
Gold Standard Diagnostics is proud to announce the release of AIX1000® Version 2.1, a major upgrade to its flagship RPR automation platform. This release introduces extra high titer capability, now supporting screens and titers up to 1:2048, a breakthrough in syphilis detection and treatment monitoring—especially for late-stage and Neurosyphilis cases.
The expanded titer range empowers laboratories to more accurately track antibody levels over time, improving clinical decision-making and supporting public health initiatives focused on syphilis control and eradication.
This AIX1000® 2.1 upgrade is the first and only FDA cleared automated test system to meet the 2024 CDC Laboratory Recommendations for Syphilis Testing "Recommendation for endpoint titers. Endpoint titers (the highest dilution yielding a reactive result) should be determined and clearly reported when testing serum with nontreponemal (lipoidal antigen) assays that detect antibodies to lipoidal antigens (i.e., rapid plasma reagin and Venereal Disease Research Laboratory).1"
More on EntSun News
"Extra high titer testing is vital for improving detection of late-stage or Neurosyphilis cases, tracking the effectiveness of syphilis treatment over time, and supporting public health need for endpoint titers" said Sean Hoesterey, Vice President of Commercial Operations, at Gold Standard Diagnostics.
In addition to the enhanced titer range, AIX1000® 2.1 delivers a suite of workflow and data management improvements designed to streamline operations and improve clarity:
The AIX1000® 2.1 software is fully compatible with:
Gold Standard Diagnostics was the first FDA cleared automated RPR testing platform in 2015 and continues to lead innovation in automated RPR testing, delivering precision, speed, and reliability to clinical laboratories worldwide.
More on EntSun News
For more information, email Gsd.info@us.goldstandarddiagnostics.com or contact your GSD representative.
For media inquiries, please contact:
Sarah Siegel
Marketing Communications Specialist
sarah.siegel@us.goldstandarddiagnostics.com
(707) 239-2863
1Papp J. R. et al. 2024. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep., 73(No. RR-1):1–32. DOI: http://dx.doi.org/10.15585/mmwr.rr7301a1 (https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fdx.doi.org%2F10.15585%2Fmmwr.rr7301a1&data=05%7C02%7C%7C146e2af518cb40e2b79108de0c1bf10a%7C19e5846425f4437da9d21182f30f78eb%7C0%7C0%7C638961511313225122%7CUnknown%7CTWFpbGZsb3d8eyJFbX...).
Gold Standard Diagnostics is proud to announce the release of AIX1000® Version 2.1, a major upgrade to its flagship RPR automation platform. This release introduces extra high titer capability, now supporting screens and titers up to 1:2048, a breakthrough in syphilis detection and treatment monitoring—especially for late-stage and Neurosyphilis cases.
The expanded titer range empowers laboratories to more accurately track antibody levels over time, improving clinical decision-making and supporting public health initiatives focused on syphilis control and eradication.
This AIX1000® 2.1 upgrade is the first and only FDA cleared automated test system to meet the 2024 CDC Laboratory Recommendations for Syphilis Testing "Recommendation for endpoint titers. Endpoint titers (the highest dilution yielding a reactive result) should be determined and clearly reported when testing serum with nontreponemal (lipoidal antigen) assays that detect antibodies to lipoidal antigens (i.e., rapid plasma reagin and Venereal Disease Research Laboratory).1"
More on EntSun News
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- BOHO Design Rentals Launches Luxury Sofa Rentals in Denver
- Bay Street Yard announces New Year's Eve Celebration
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
"Extra high titer testing is vital for improving detection of late-stage or Neurosyphilis cases, tracking the effectiveness of syphilis treatment over time, and supporting public health need for endpoint titers" said Sean Hoesterey, Vice President of Commercial Operations, at Gold Standard Diagnostics.
In addition to the enhanced titer range, AIX1000® 2.1 delivers a suite of workflow and data management improvements designed to streamline operations and improve clarity:
- Reflex Runs After Worklist Completion
- Automatic Next Actions
- Improved LIS Communication – Easier for LIS systems to interpret run data
- Enhanced Data Analysis
- Faster Backup and Restore
- Bleach Maintenance Support – Compatible with the GSD Bleach (Cat # SHW-20)
- Optional Text and Email Notifications for Errors
The AIX1000® 2.1 software is fully compatible with:
- Gold Standard Diagnostics Rapid Plasma Reagin (RPR) Test System (Cat # GSD01-1600)
- GSD Bleach (Cat # SHW-20)
- GSD RPR Diluent (Cat # GSD01-1600-DIL)
Gold Standard Diagnostics was the first FDA cleared automated RPR testing platform in 2015 and continues to lead innovation in automated RPR testing, delivering precision, speed, and reliability to clinical laboratories worldwide.
More on EntSun News
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks
- Clean Comedy Kings Debuts At Black Oak Casino Saturday January 3rd
For more information, email Gsd.info@us.goldstandarddiagnostics.com or contact your GSD representative.
For media inquiries, please contact:
Sarah Siegel
Marketing Communications Specialist
sarah.siegel@us.goldstandarddiagnostics.com
(707) 239-2863
1Papp J. R. et al. 2024. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep., 73(No. RR-1):1–32. DOI: http://dx.doi.org/10.15585/mmwr.rr7301a1 (https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fdx.doi.org%2F10.15585%2Fmmwr.rr7301a1&data=05%7C02%7C%7C146e2af518cb40e2b79108de0c1bf10a%7C19e5846425f4437da9d21182f30f78eb%7C0%7C0%7C638961511313225122%7CUnknown%7CTWFpbGZsb3d8eyJFbX...).
Source: Gold Standard Diagnostics, LLC
0 Comments
Latest on EntSun News
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- Sip and Frost Cake Bar Announces New Partnership with Tommy Nobis Center Academy
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- The Rise of Experience Gifting: Families Choosing Memories Over More Stuff This Christmas
- Delirious Comedy Club And House Of Magic Expand To New Larger Location At Silver Sevens
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
- Celebrate Festively with Christmas Eyeglasses
- ZEELOOL Show Stopper Glasses: Own the Holiday Spotlight
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- Forgotten: Mysteries Of The 18th Century Releases On TubiTV, DVD & Blu-Ray
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- WVU Students Shatter World Record with 100-Day Film "The Freedom of Uselessness"